VU-0152099: Difference between revisions

From WikiMD's Wellness Encyclopedia

Newer edit →
CSV import
 
CSV import
Line 1: Line 1:
{{Infobox drug
== VU-0152099 ==
| name = VU-0152099
| image = <!-- Image of the chemical structure -->
| width = 250px
| alt =
| caption = Chemical structure of VU-0152099
| IUPAC_name = <!-- IUPAC name -->
| CAS_number = <!-- CAS number -->
| PubChem = <!-- PubChem ID -->
| ChemSpiderID = <!-- ChemSpider ID -->
| UNII = <!-- UNII -->
| KEGG = <!-- KEGG ID -->
| ChEMBL = <!-- ChEMBL ID -->
| C= <!-- Number of carbon atoms -->
| H= <!-- Number of hydrogen atoms -->
| N= <!-- Number of nitrogen atoms -->
| O= <!-- Number of oxygen atoms -->
| molecular_weight = <!-- Molecular weight -->
}}


'''VU-0152099''' is a chemical compound that acts as a selective positive allosteric modulator of the [[metabotropic glutamate receptor 4]] (mGluR4). It is primarily used in scientific research to study the role of mGluR4 in the central nervous system and its potential therapeutic applications.
VU-0152099 is a chemical compound that acts as a selective positive allosteric modulator of the metabotropic glutamate receptor subtype 4 (mGluR4). It has been studied for its potential therapeutic effects in various neurological disorders.


== Pharmacology ==
== Chemical Properties ==
VU-0152099 enhances the activity of mGluR4, a receptor that is part of the group III metabotropic glutamate receptors. These receptors are G-protein coupled receptors that modulate neurotransmission in the brain. mGluR4 is predominantly expressed in the [[cerebellum]], [[thalamus]], and [[hippocampus]], and is involved in the regulation of [[glutamate]] release.


The modulation of mGluR4 by VU-0152099 has been shown to have potential therapeutic effects in models of [[Parkinson's disease]], [[anxiety]], and [[pain]]. By enhancing mGluR4 activity, VU-0152099 may help to reduce excessive glutamate release, which is implicated in neurodegenerative diseases and excitotoxicity.
VU-0152099 is characterized by its specific chemical structure, which allows it to selectively interact with mGluR4. The compound is often used in research settings to explore the role of mGluR4 in the central nervous system.


== Mechanism of Action ==
== Mechanism of Action ==
VU-0152099 binds to an allosteric site on the mGluR4 receptor, distinct from the orthosteric site where glutamate binds. This binding increases the receptor's response to glutamate, thereby potentiating its signaling pathways. The positive allosteric modulation of mGluR4 can lead to decreased release of excitatory neurotransmitters, providing a neuroprotective effect.


== Research Applications ==
As a positive allosteric modulator, VU-0152099 enhances the activity of mGluR4 by binding to a site distinct from the orthosteric site. This modulation can lead to increased receptor activity in the presence of the natural ligand, glutamate. The precise mechanism involves altering the receptor conformation to favor active states.
VU-0152099 is used in preclinical research to explore the therapeutic potential of mGluR4 modulation. Studies have demonstrated its efficacy in animal models of [[Parkinson's disease]], where it helps to alleviate motor symptoms by modulating basal ganglia circuits. Additionally, its anxiolytic and analgesic properties are being investigated for potential use in treating anxiety disorders and chronic pain.
 
== Research and Applications ==
 
Research involving VU-0152099 has primarily focused on its potential in treating neurological conditions such as Parkinson's disease, anxiety, and schizophrenia. Studies have shown that mGluR4 modulation can have neuroprotective effects and may help in reducing symptoms associated with these disorders.
 
=== Parkinson's Disease ===
 
In models of Parkinson's disease, VU-0152099 has been shown to reduce motor deficits and protect dopaminergic neurons. This suggests that mGluR4 modulation could be a promising strategy for developing new treatments for Parkinson's disease.
 
=== Anxiety and Schizophrenia ===
 
The compound has also been investigated for its effects on anxiety and schizophrenia. By modulating glutamatergic signaling, VU-0152099 may help in alleviating symptoms associated with these conditions.


== Safety and Toxicology ==
== Safety and Toxicology ==
As a research compound, VU-0152099 is not approved for clinical use in humans. Its safety profile is primarily characterized in animal studies, where it has shown a favorable safety margin. However, further studies are needed to fully understand its pharmacokinetics and potential side effects.


== Also see ==
While VU-0152099 has shown promise in preclinical studies, its safety profile in humans is not fully established. Further research is needed to determine its potential side effects and long-term safety.
 
== Related Pages ==
 
* [[Metabotropic glutamate receptor]]
* [[Metabotropic glutamate receptor]]
* [[Allosteric modulator]]
* [[Allosteric modulator]]
* [[Parkinson's disease]]
* [[Parkinson's disease]]
* [[Neurotransmitter]]
* [[Schizophrenia]]


{{Receptor modulators}}
== References ==
{{Neuroscience}}


{{Reflist}}
[[Category:Chemical compounds]]
[[Category:Neuroscience]]
[[Category:Pharmacology]]
[[Category:Pharmacology]]
[[Category:Neuroscience]]
[[Category:Research chemicals]]

Revision as of 11:56, 9 February 2025

VU-0152099

VU-0152099 is a chemical compound that acts as a selective positive allosteric modulator of the metabotropic glutamate receptor subtype 4 (mGluR4). It has been studied for its potential therapeutic effects in various neurological disorders.

Chemical Properties

VU-0152099 is characterized by its specific chemical structure, which allows it to selectively interact with mGluR4. The compound is often used in research settings to explore the role of mGluR4 in the central nervous system.

Mechanism of Action

As a positive allosteric modulator, VU-0152099 enhances the activity of mGluR4 by binding to a site distinct from the orthosteric site. This modulation can lead to increased receptor activity in the presence of the natural ligand, glutamate. The precise mechanism involves altering the receptor conformation to favor active states.

Research and Applications

Research involving VU-0152099 has primarily focused on its potential in treating neurological conditions such as Parkinson's disease, anxiety, and schizophrenia. Studies have shown that mGluR4 modulation can have neuroprotective effects and may help in reducing symptoms associated with these disorders.

Parkinson's Disease

In models of Parkinson's disease, VU-0152099 has been shown to reduce motor deficits and protect dopaminergic neurons. This suggests that mGluR4 modulation could be a promising strategy for developing new treatments for Parkinson's disease.

Anxiety and Schizophrenia

The compound has also been investigated for its effects on anxiety and schizophrenia. By modulating glutamatergic signaling, VU-0152099 may help in alleviating symptoms associated with these conditions.

Safety and Toxicology

While VU-0152099 has shown promise in preclinical studies, its safety profile in humans is not fully established. Further research is needed to determine its potential side effects and long-term safety.

Related Pages

References

<references group="" responsive="1"></references>

Retrieved from "https://wikimd.com/index.php?title=VU-0152099&oldid=6199762"